Biomarkers to Guide First-Line Treatment in HER2+ Gastroesophageal Cancer: Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, highlighted how HER2 expression level and PD-L1 status guided first-line treatment selection for HER2-positive gastroesophageal adenocarcinoma following the August 2026 FDA approval of zanidatamab-hrii (Ziihera)–based regimens. In the phase 3 HERIZON-GEA-01 trial (NCT05152147), zanidatamab plus chemotherapy, with or without tislelizumab-jsgr (Tevimbra), improved PFS and OS vs trastuzumab (Herceptin) plus chemotherapy. She noted that the comparator arm did not include pembrolizumab plus trastuzumab and chemotherapy, a US standard approved for tumors with a PD-L1 combined positive score (CPS) of at least 1 based on the phase 3 KEYNOTE-811 trial (NCT03615326). Janjigian cautioned against using zanidatamab plus chemotherapy without immunotherapy in patients with HER2 immunohistochemistry 2+/in situ hybridization–positive tumors, citing less favorable outcomes in that subgroup. Because the zanidatamab-based combinations require no minimum CPS, she added that they remained an option for patients with CPS 0 disease, although this is rare among HER2-positive tumors.
Early Predictors of Vorasidenib Response in IDH-Mutant Low-Grade Glioma: Francesco Bruno, MD, PhD
Francesco Bruno, MD, PhD, of the University of Turin, detailed findings from a prospective study of early predictors of response to vorasidenib (Voranigo) in 54 patients with IDH-mutant grade 2 glioma treated through an expanded access program, presented at the 2026 Society for Neuro-Oncology Annual Meeting. The objective response rate was 17.0% with bidimensional MRI (median time to response, 11.5 months), 28.3% with volumetric MRI (5.7 months), and 76.5% with 18F-DOPA PET (n = 13 of 17 measurable patients; 3.2 months). Among 12 patients with active seizures at treatment start, 11 (92%) had a seizure response, with a median time to response of 28 days. Early seizure response preceded tumor shrinkage on MRI at 3 and 6 months (P = .009 for both), consistent with exploratory analyses from the phase 3 INDIGO trial (NCT04164901). Bruno noted that layered monitoring could provide earlier evidence of drug activity in this slow-growing disease, with seizure control serving as the fastest marker of response.
Oral SERD Implementation in Early-Stage HR+ Breast Cancer: Neil Iyengar, MD
Neil Iyengar, MD, of Winship Cancer Institute of Emory University, outlined efficacy, sequencing, and tolerability considerations for oral selective estrogen receptor degraders (SERDs) in early-stage hormone receptor–positive breast cancer. In the phase 3 lidERA trial (NCT04961996), adjuvant giredestrant (Wilserdly) reduced the risk of invasive disease recurrence or death by 30% vs standard endocrine therapy among 4170 patients with estrogen receptor–positive, HER2-negative stage I to III breast cancer (HR, 0.70; 95% CI, 0.57-0.87; P = .0014). The 3-year invasive disease-free survival rates were 92.4% vs 89.6%, respectively, and treatment discontinuations due to adverse effects occurred in 5.3% vs 8.2% of patients. An FDA decision on giredestrant in this setting was anticipated by November 30, 2026. Iyengar noted that the optimal timing of switch strategies, potentially prompted by emergence of ESR1 mutations, remained an open question, and that better tolerability with oral SERDs could improve long-term adherence.
The Rationale Behind the OPTIC Trial in CML: Jorge Cortes, MD
Jorge Cortes, MD, of the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, reviewed the rationale behind and 5-year follow-up data from the phase 2 OPTIC trial (NCT02467270) of response-based ponatinib (Iclusig) dosing in chronic-phase chronic myeloid leukemia resistant to at least 2 prior TKIs or harboring a BCR::ABL1 T315I mutation. Patients were randomly assigned to starting doses of 45 mg (n = 94), 30 mg (n = 95), or 15 mg (n = 94) daily, with the 45- and 30-mg arms reduced to 15 mg upon achieving a BCR::ABL1 response of 1% or less. Twelve-month BCR::ABL1 response rates were 60%, 41%, and 40%, respectively, and were 64%, 25%, and 16% among patients with T315I mutations. Cortes noted that exposure-adjusted arterial occlusive event rates were similar with the 45- and 30-mg doses, suggesting that the 30-mg dose could compromise efficacy without improving safety. Starting at 45 mg and reducing to 15 mg upon response is now the approved label dosing, which he recommended in practice.